Annexon

Q2 FY2026 EarningsQ2 FY26 missed consensus expectations on the bottom line, with a net loss of $55.3M vs. $45.9M expected and GAAP EPS of -$0.28 vs. -$0.24. Despite the wider-than-expected loss driven by accelerated ARCHER II trial costs and pre-commercial consulting, the company secured a $200M credit facility extending its cash runway into 2028. Key pipeline milestones remain on track, including a BLA submission for Tanruprubart in Q4 2026.